Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Current Taxes (2016 - 2025)

Gsk has reported Current Taxes over the past 10 years, most recently at $662.4 million for Q4 2025.

  • Quarterly results put Current Taxes at $662.4 million for Q4 2025, down 26.59% from a year ago — trailing twelve months through Dec 2025 was $662.4 million (down 26.59% YoY), and the annual figure for FY2025 was $662.4 million, down 26.59%.
  • Current Taxes for Q4 2025 was $662.4 million at Gsk, down from $902.3 million in the prior quarter.
  • Over the last five years, Current Taxes for GLAXF hit a ceiling of $902.3 million in Q4 2024 and a floor of $552.4 million in Q4 2022.
  • Median Current Taxes over the past 5 years was $659.2 million (2021), compared with a mean of $679.4 million.
  • Biggest five-year swings in Current Taxes: surged 45.4% in 2024 and later decreased 26.59% in 2025.
  • Gsk's Current Taxes stood at $659.2 million in 2021, then fell by 16.19% to $552.4 million in 2022, then rose by 12.33% to $620.6 million in 2023, then surged by 45.4% to $902.3 million in 2024, then decreased by 26.59% to $662.4 million in 2025.
  • The last three reported values for Current Taxes were $662.4 million (Q4 2025), $902.3 million (Q4 2024), and $620.6 million (Q4 2023) per Business Quant data.